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Abstract
Background: The purpose of this study is to modulate the transfection efficiency of adenovirus (Ad) on the cornea by the
covalent attachment of chitosan on adenoviral capsids via a thioether linkage between chitosan modified with 2-
iminothiolane and Ad cross-linked with N-[c-maleimidobutyryloxy]succinimide ester (GMBS).
Methodology/Principal Findings: Modified Ad was obtained by reaction with the heterobifunctional crosslinking reagent,
GMBS, producing maleimide-modified Ad (Ad-GMBS). Then, the chitosan-SH was conjugated to Ad-GMBS via a thioether
bond at different ratios of Ad to GMBS to chitosan-SH. The sizes and zeta potentials of unmodified Ad and chitosan-
modified Ads were measured, and the morphologies of the virus particles were observed under transmission electron
microscope. Primary cultures of bovine corneal epithelial cells were transfected with Ads and chitosan-modified Ads in the
absence or presence of anti-adenovirus antibodies. Chitosan modification did not significantly change the particle size of
Ad, but the surface charge of Ad increased significantly from 224.3 mV to nearly neutral. Furthermore, primary cultures of
bovine corneal epithelial cells were transfected with Ad or chitosan-modified Ad in the absence or presence of anti-Ad
antibodies. The transfection efficiency was attenuated gradually with increasing amounts of GMBS. However, incorporation
of chitosan partly restored transfection activity and rendered the modified antibody resistant to antibody neutralization.
Conclusions/Significance: Chitosan can provide a platform for chemical modification of Ad, which offers potential for
further in vivo applications.
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Introduction
Gene delivery to the three major cell types of the cornea using
viral and non-viral methods has been demonstrated in vivo and in
vitro [1]. Viral and non-viral vectors have their own advantages
and limitations. For example, recombinant adenovirus (Ad) has
been extensively evaluated in gene delivery to the cornea in many
studies [2–8]. This method can achieve a high level of transgene
expression, but immune responses may be raised against Ad
proteins, thereby limiting further administration of the virus. In
contrast, non-viral cationic polymer vectors can bind to the
negatively charged cell surface, but their application in corneal
gene delivery may be limited by cytotoxicity and low infection
efficiency.
Various approaches have been developed to modify Ad tropism.
New generations of Ad vectors have been designed to lower their
immunogenicity. In one approach, the capsid proteins of Ad are
chemically modified with polymers. Modification of Ad vectors
with polyethylene glycol (PEG) prolongs extended circulation
kinetics in murine models and circumvents neutralization of the
Ad vectors by antibodies. The activated PEG reacts preferentially
with the e-amino termini of lysine residues on the capsid,
specifically the hexon, fiber, and penton base proteins [9–14].
Furthermore, PEGylated Ad vectors attenuate the ability of the
vector to be taken up by antigen-presenting cells, thereby reducing
inflammatory responses. Animals administered PEGylated Ad
vectors exhibit reduced levels of both cell-mediated and humoral
immune responses, resulting in significant transgene expression on
re-administration of unmodified Ad vectors in the lung [15,16].
However, PEGylation of Ad vectors leads to reduced infectivity
due to steric hindrance from flexible PEG chains [9–11,14–18].
Ad vectors coated with polymers other than PEG have also been
developed. Seymour et al. used a multivalent hydrophilic polymer
based on poly[N-(2-hydroxypropyl)methacrylamide] (pHPMA) to
modify Ad vectors [19–22]. These modified vectors also show
extended plasma circulation time, reduced toxicity, and evasion of
neutralizing antibodies.
Chitosan has been proposed for parenteral drug delivery and
mucosal drug delivery due to its unique biological properties, such
as the ability to adhere to mucus, to permeate mucosal barriers, and
to be biodegraded in the rich lysozyme-containing mucus [23,24].
These features are important for the application of chitosan to the
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delivery to the cornea and ocular surface have demonstrated
enhancement of adenoviral infectivity by using a noncovalent
complex consisting of chitosan [25,26]; however, chitosan has not
yet been used for the chemical modification of Ad.
The purpose of this study was to covalently modify a
recombinant Ad encoding a transgene with chitosan, to shield
the vector from recognition by anti-Ad antibodies, and to ablate
the pathways that Ad normally activates. Chitosan, a cationic
natural polymer, was chosen to modify adenoviral capsids because
it would change the Ad surface charge from negative to neutral or
positive, facilitating attachment of the modified Ad to the
negatively charged cell membrane.
Materials and Methods
Biological and chemical reagents
Most culture reagents, including Dulbecco’s Modified Eagle
Medium(DMEM)/F-12(Ham)16,L-glutamine,HEPES,DMEM,
D-glucose, sodium pyruvate, TrypLETM Express, phenol red, fetal
bovine serum, Escherichia coli LPS, penicillin-streptomycin
(10,000 U/mL), fungizone antimycotic, amphotericin B (250 mg/
mL), insulin-transferrin-selenium supplement, and gentamicin
solution, werepurchasedfromInvitrogen (Carlsbad,CA). Chemical
reagents used in this study included Dispase II (Roche, Mannheim,
Germany), rabbit polyclonal antibody to Ad type 5 (Abcam,
Cambridge, UK), chitosan oligosaccharide lactate, (Mn,5,000,
Sigma-Aldrich, St. Louis, MO), 2-iminothiolane hydrochloride
(Sigma-Aldrich), N-[c-maleimidobutyryloxy]succinimide ester
(GMBS, Pierce, Rockford, IL), phosphate-buffered saline (PBS),
DL-dithiothreitol (DTT, Sigma-Aldrich), and 5,59-dithiobis-(2-
nitrobenzoic acid) (DTNB, MP Biomedicals, Solon, OH).
Primary culture of bovine corneal epithelial cells
The methods used for primary culture of bovine corneal
epithelial cells were described previously [27,28]. Briefly, eyes of
domestic adult cattle were obtained from the local slaughterhouse,
sterilized with povidone-iodine solution for 3 to 5 minutes to avoid
contamination, and washed with sterile Dulbecco’s PBS (DPBS).
The harvested corneas were placed epithelial side down in
sterilized dishes and incubated in DMEM/F12 with Dispase II
at 37uC for 30 to 40 minutes. The loosened epithelial cells were
scraped gently using a cell scraper. The cells were washed, seeded
onto the cell culture dishes (Corning, NY), and incubated at 37uC
in a humidified atmosphere of 95% air/5% CO2. The routine
culture medium was DMEM/F12 containing 10% FBS, 100 U/
mL penicillin, 100 mg/mL streptomycin, 0.25 mg/mL fungizone,
1% insulin-transferrin-selenium supplement and 50 mg/mL gen-
tamicin. The medium was changed every 2 to 3 days.
Modification of chitosan with 2-iminothiolane
Fifty micrograms of chitosan oligosaccharide lactate (0.28 mEq
of NH2 group) and 0.341 g 2-iminothiolane were dissolved in
50 mL 0.1 M sodium acetate buffer (pH 6.0) at room tempera-
ture. The resulting polymer conjugates were dialyzed in a dialysis
membrane bag with a molecular weight cutoff of 3500 Daltons
(Spectrum, Philadelphia, PA, USA) against 0.1 M potassium
phosphate buffer containing 10 mM DTT at pH 7.4. The degree
of modification was determined by quantifying the thiol groups on
the modified chitosan with Ellman’s reagent [29,30].
Modification of Ad with GMBS and chitosan
The Ad used in this study was AdCMV-gfp (Qbiogene,
Carlsbad, CA), an E1-, E3-deleted Ad5 recombinant expressing
green fluorescent protein (GFP) under the control of a cytomeg-
alovirus (CMV) promoter. Because the hexon is the major
component of the Ad capsid and is 20-fold more abundant than
the knobbed fiber protein in biomedical copy number [31], the
lysine residues on the hexon proteins are reasonably considered
the major linkage sites of GMBS. Thus, for each mg of purified Ad,
0.38 nEq of viral lysine residues are present, based on the formula:
Lysine content=(weight of Ad)6(number of lysine residues in
hexon protein sequence)/(molecular weight of hexon protein on
viral capsids). Different amounts of the heterobifunctional cross-
linking reagent GMBS were conjugated to the Ads with gentle
vortexing at room temperature for 30 minute. Subsequently,
different amounts of chitosan-SH were mixed with Ad-GMBS, as
listed in Table 1, and the mixtures were reacted at room
temperature for 2 hours. The sizes and zeta potentials of
unmodified Ads and chitosan-modified Ads were determined by
a dynamic light scattering (DLS) mthod with a Zetasizer 3000
(Malvern, Worcestershire, UK) [32]. A schematic diagram of
covalently modified Ad and chitosan is shown in Fig. 1.
Morphological investigation by transition electron
microscopy
Unmodified Ads and chitosan-modified Ads were processed for
transmission electron microscopy using a negative stain technique
[21]. Ten-microliter drops of the freshly prepared samples were
placed on copper grids coated with carbon and formvar (EMS,
Table 1. Comparison of different reaction amounts of GMBS and chitosan-SH to yield different Ad/GMBS/ChiSH ratios.
Reaction
mixture Ad (mg)
Moles of lysine on Ad
(nmol)
GMBS in DMSO
(mg)
Moles of GMBS
(nmol) ChiSH (ml)
Moles of thiol group
(nmol)
Ad/GMBS/ChiSH
ratio
I 1 0.38 0.1 0.38 1 2.62 1:1:7
II 1 0.38 0.1 0.38 10 26.2 1:1:70
III 1 0.38 0.1 0.38 100 262 1:1:700
IV 1 0.38 1.0 3.8 1 2.62 1:10:7
V 1 0.38 1.0 3.8 10 26.2 1:10:70
VI 1 0.38 1.0 3.8 100 262 1:10:700
VII 1 0.38 10 38 1 2.62 1:100:7
VIII 1 0.38 10 38 10 26.2 1:100:70
IX 1 0.38 10 38 100 262 1:100:700
doi:10.1371/journal.pone.0012085.t001
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paper and replaced with 2% phosphotungstic acid (pH 7.0) for
30 s. After removal of this solution, the grids were allowed to dry
and were imaged with a transmission electron microscope
(Hitachi, Tokyo, Japan).
Infection efficiency assay
Bovine corneal epithelial cells were seeded onto a 6-well culture
plate (TPP, Trasadingen, Switzerland) at a density of 2610
5 cells/
well for the infection efficiency assay. After incubation for
24 hours, these cells were transfected with unmodified Ad or a
range of chitosan-modified Ads from different reaction mixtures
(Table 1) in 2 mL of medium (final volume) with a serial
multiplicity of infection (MOI) of 200, 1000 or 5000 Ad
particles/cell. To investigate cell infection in the presence of
neutralizing antibody, rabbit polyclonal antibody to Ad type 5 was
added to the medium at 2 ng/mL. After 24 hours, the cells were
harvested, washed with DPBS, treated with TrypLE
TM Express,
and resuspended in 1 mL of DPBS for flow-cytometric analysis of
GFP expression with a FACScan flow cytometer (Becton
Dickinson, San Joes, CA). The presence or absence of staining
was determined by comparison with the untreated control cells.
The data acquisition and analysis were performed using Cellquest
software (Becton Dickinson, San Joes, CA). The relative
fluorescence intensity of chitosan-modified Ad was defined as the
magnitude of the mean fluorescence intensity greater than that of
control cells divided by that of the unmodified Ad. In addition, the
infected cells were observed and imaged with an inverted
microscope (model 1671, Olympus, Tokyo, Japan) equipped with
a digital camera.
In vivo infection
The animal experiments were conducted according to the Guide
for the Care and Use of Laboratory Animals and were approved by
the National Taiwan University College of Medicine and College of
Public Health Institutional Animal Care and Use Committee
(IACUC 20060052). All experiments conformed to the ARVO
Statement for the Use of Animals in Ophthalmic and Vision
Research. To test the ability of chitosan-modified Ads to transfect
cells, transgene expression in corneal epithelial cells was evaluated
by observing the GFP expression after incubation with Ad-GMBS
at a ratio of 1:100 and Ad-GMBS-ChiSH at a ratio of 1:100:700 at
1000 Ad particles/cell. Sprague-Dawley rats, 6 to 8 weeks old and
weighing 200 to 250 g, were used in this study, and each group
consisted of six animals. Six immune rats had previously been
instilled intranasally with 10
9 infectious units of a replication-
defective type 2 adenovirus encoding GFP (AdCMV-gfp) and had
titers to Ad in the range of 25,000–50,000. Naive rats had not been
exposed to the Ad vector. All animals in the immunized group were
subjected to tail vein puncture on the day of instillation, and the
blood was analyzed for antibody titers. Titers of neutralization
antibodies to AdCMV-gfp in serum preparations were determined
by a microneutralization test performed in 96-well microtiter plates
with continuous HEK 293 cells, which had been generated by
transformation of human embryonic kidney cell cultures. Titers of
sera were determined by a neutralization assay on sera serially
diluted 2-fold, beginning with a 1:2 dilution [15,33]. Diluted
AdCMV-gfpwith a TCID50 value of100wasincubatedwith2-fold
dilutions of sera and inoculated into HEK 293 cells. They were
examined after a 72- to 96-hour incubation, and the end point was
the highest dilution of sera that inhibited CPE when compared with
control tubes containing no antiserum. Data are reported as the
reciprocal titer interpolated from duplicate assays. All samples were
tested in duplicate.
The contralateral left eye without treatment was used as a
control. After topical application for 1 day, eyes were obtained and
embedded in gelatin capsules containing Tissue-Tek (OCT
Compound 4583; Sakura Fine Tek Europe BV, Zoeterwoude,
Netherlands) and frozen in liquid nitrogen. Serial 8-mm-thick
cryostat sections were taken across the eyeballs along the optical
axis. The transgene expressions were evaluated by fluorescence
microscopy (DM L; Leica, Wetzlar, Germany) for Ad-GMBS at a
ratio of 1:100 and Ad-GMBS-ChiSH at a ratio of 1:100:700. Both
right (treated) and left (control) eyes from each animal were
evaluated in duplicate.
Results
Characterization of chitosan-modified Ad
In the present study, the covalent attachment of chitosan on Ad
was achieved by first modifying chitosan with 2-iminothiolane and
cross-linking Ad to GMBS, and subsequently conjugating thiolated
chitosan to the GMBS-modified Ad by thioether formation. The
amount of 2-iminothiolane immobilized on the chitosan was
quantitatively determined using Ellman’s method [34]. The degree
of modification was 2.62 mEq SH/g chitosan.
Figure 1. Schematic diagram of covalently modified Ad and chitosan with GMBS and 2-iminothiolane, respectively.
doi:10.1371/journal.pone.0012085.g001
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modified Ads with different Ad/GMBS/ChiSH ratios. When
compared to the average size of unmodified Ads (about 120 nm),
dynamic light scattering analysis showed that the average size of
chitosan-modified Ads gradually increased with increasing amounts
of GMBS or/and chitosan. The size distribution of each point was
small, excluding the possibility of aggregation. Fig. 2 also shows the
surface charge, determined by the measurement of zeta potential, of
unmodified and modified Ads. The net surface charge of the Ad
capsid changed from 224.3 mV to nearly neutral. In addition, the
morphologies of unmodified Ads and chitosan-modified Ads were
observed using transmission electron microscopy. Fig. 3 shows the
photomicrographs of unmodified Ads and chitosan-modified Ads.
The size of chitosan-modified Ad particles increased with the
amount of GMBS. Chitosan-modified Ads exhibited a rough and
irregular appearance compared to the round shape of unmodified
Ads. The morphology of chitosan-modified Ads correlated with the
size and size distribution by DLS. The gradual increase in particle
size with the amount of GMBS or/and chitosan and neutralization
of the viral surface charges may be evidence that the chitosan and
Ad were conjugated via GMBS.
Infection efficiency of chitosan-modified Ad
To test whether chitosan-modified Ad was able to infect cells
and to examine infection efficiency, the expression of GFP was
assessed after infecting primary cultured corneal epithelial cells
with different GMBS ratios (Fig. 4). Control corneal epithelial cells
showed normal phenotypes and no green fluorescence, as expected
(data not shown). Flow-cytometric analysis of GFP expression
showed that the infection efficiency of chitosan-modified Ads was
dose-dependent (Fig. 5). When infected with 1000 Ad particles/
cell, corneal epithelial cells infected with chitosan-modified Ads at
a 1:100:7 Ad/GMBS/ChiSH ratio did not show any detectable
fluorescence signal 24 hours after infection, whereas other cells
showed bright fluorescence. When infected with 200 Ad particles/
cell, the infection efficiency decreased as the amount of GMBS
increased. The infection efficiencies of chitosan-modified Ads at
1:10:7 and 1:10:70 Ad/GMBS/ChiSH ratios were approximately
20–30% lower than that of unmodified Ad. Gene expression of
chitosan-modified Ad at 1:100:7 and 1:100:70 Ad/GMBS/ChiSH
ratios fell markedly. Therefore, the ability of Ad to infect corneal
epithelial cells was essentially ablated by the modification
procedure at higher ratios of GMBS to Ad.
Chitosan partially restores infection activity
To determine whether the amount of chitosan could affect the
ability of chitosan-modified Ad to transfect cells, transgene
expression in corneal epithelial cells was examined after incubation
with increasing amounts of chitosan at a 1:100 Ad-GMBS ratio and
1000 Ad particles/cell (Fig. 6). Cells treated with 1:100 Ad-GMBS
in the absence of chitosan generated 810-fold lower GFP expression
than unmodified Ad-treated cells (Fig. 6I). In contrast, cells infected
with chitosan-modified Ad expressed GFP in a chitosan-dependent
manner. The greatest transgene expression was from Ad-GMBS-
ChiSH at a ratio of 1:100:700. The infection efficiencies and the
mean fluorescence intensities increased with increasing amounts of
chitosan(Figs.6Iand 6J).However,the infectionefficienciesand the
mean fluorescence intensities resulting from transfection with
chitosan-modified Ads were still much lower than those of the
unmodified Ads. Therefore, higher amounts of chitosan partially
restored infection ability.
Infection efficiency in the presence of neutralizing
antibody
Fig.7 shows the infection efficiencies of unmodified and chitosan-
modified Ads in the absence or presence of neutralizing antibody
against Ad capsid protein. Neutralizing antibody at 2 ng/mL was
sufficient to reduce the infection efficiencies and the relative
fluorescence intensities resulting from infection with either unmod-
ified Ad or chitosan-modified Ads, except with Ad-GMBS-ChiSH
at a ratio of 1:100:700 (Fig. 8). Therefore, the ability of chitosan to
evade neutralizing antibodies appeared to work inthepresentstudy.
In vivo infection assay
The chitosan-modified Ad and GMBS-modified Ad without
further chitosan modification were applied to corneal infection in
Figure 2. Variations of chitosan-modified Ad at different Ad:GMBS and Ad:GMBS:ChiSH ratios. For size, each point represents the
particle number mean 6 S.E.M. For zeta potential, each point represents the mean of zeta potential 6 S.E.M (n=100).
doi:10.1371/journal.pone.0012085.g002
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signals of corneal histology. As expected, sections of Ad-GMBS
(1:100)–treated eyes from two of six rats demonstrated a weak
fluorescence signal (Fig. 9D). Sections from Ad-GMBS-ChiSH
(1:100:700)–treated eyes revealed fluorescence localized through-
out the corneal and conjunctival epithelial cells in all six rats.
Corneal epithelium from Ad-GMBS-ChiSH–treated eyes was
uniformly fluorescent. In the palpebral conjunctiva, it was evenly
distributed along the entire cell, as well in the bulbal conjunctiva
(Fig. 9E). Rats were immunized with Ad vectors by intranasal
instillation, and serum antibody titers were monitored over time.
In general, the antibody titers were between 25,000 and 50,000 at
the time of challenge with Ad-GMBS-ChiSH (1:100:700). The
period between immunization and secondary challenge was 5
weeks. Corneal sections treated with Ad-GMBS-ChiSH
(1:100:700) revealed strong fluorescence localized throughout the
corneal epithelial cells uniformly in all six rats (Fig. 9F).
Discussion
To our knowledge, this is the first report on the modification of
the surface of Ad using chitosan to ablate binding between the Ad
and cells, to shield the Ad from neutralizing antibodies, and
possibly to permit the incorporation of new ligands for retargeting.
The possibility to retarget Ad to selected receptors provides the
opportunity to redefine its tissue tropism and distribution in vivo.
The avoidance of Ad infection in nontarget tissues would decrease
the viral load. Evasion of neutralization by pre-existing anti-Ad
antibodies can also decrease the viral load. Decreasing the viral
load may lower toxicity associated with Ad gene therapy and
improve its efficacy and safety.
The cationic property of chitosan is responsible for ionic
interactions with anionic substructures such as sialic acid and
sulfonic acid within the mucus layer, thereby conferring its
mucoadhesiveness [23]. In addition, chitosan exhibits favorable
Figure 3. Transmission electron photomicrographs of unmodified Ad (A) and chitosan-modified Ad at Ad:GMBS:ChiSH ratios of
1:1:7 (B), 1:10:7 (C), and 1:100:7 (D). Magnification=80,0006. Scale bar=100 nm.
doi:10.1371/journal.pone.0012085.g003
Figure 4. Fluorescence photomicrographs of primary cultured corneal epithelial cells. Primary cultured corneal epithelial cells infected by
unmodified Ad (A)–(C) or chitosan-modified Ad at Ad:GMBS:ChiSH ratios of 1:1:7 (D)–(F), 1:10:7 (G)–(I), and 1:100:7 (J)–(L). Magnification=1006.
doi:10.1371/journal.pone.0012085.g004
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and interesting physicochemical characteristics that make it a
unique material for the design of ocular delivery [23,35,36,37,38].
Previous studies have demonstrated enhanced Ad infectivity using
a noncovalent complex consisting of chitosan [25,26]. One of the
mechanisms proposed for this enhanced effect is that cationic
chitosan forms a complex with negatively charged Ad, and excess
positive charges in the Ad and chitosan-containing complex
enhance interactions with negatively charged cell surfaces through
electrostatic interactions. This phenomenon is consistent with our
data showing that greater amounts of chitosan restored infection
ability (Fig. 5). Therefore, we expect that the infection route of
chitosan-modified Ad into cells may occur via a receptor-
independent pathway.
In addition, previous studies using monovalent PEG or the
multivalent polymer pHPMA for conjugation to the surface of Ads
have been reported [11–16,21,22,39–41]. These modifications
have demonstrated that the loss of Ad bioactivity depends on the
degree of modification of viral lysine residues [11,14,21]. We
obtained similar results, as the infection efficiency of chitosan-
modified Ad decreased with increasing GMBS (Fig. 4). It is
reasonable to attribute the decreased infection efficiency after
modification of viral lysine residues to interference of the
Figure 5. Infection efficiencies from flow-cytometric analysis of
corneal epithelial cells infected at a MOI of 200, 1000 or 5000
Ad particles/cell with unmodified Ad or chitosan-modified Ad
at varying ratios. Each point represents the mean 6 S.D. (n=3).
doi:10.1371/journal.pone.0012085.g005
Figure 6. Phase contrast and fluorescence photomicrographs, respectively, of primary cultured corneal epithelial cells infected
with Ad-GMBS at a ratio of 1:100 (A), (E); Ad-GMBS-ChiSH at a ratio of 1:100:7 (B), (F); Ad-GMBS-ChiSH at a ratio of 1:100:70 (C), (G);
and Ad-GMBS-ChiSH at a ratio of 1:100:700 (D), (H) at 1000 Ad particles/cell. Magnification=1006. Infection efficiency (I) and relative
fluorescence intensity (J) from flow-cytometric analysis of corneal epithelial cells infected with Ad, Ad-GMBS at a ratio of 1:100, Ad-GMBS-ChiSH ata
ratio of 1:100:7, Ad-GMBS-ChiSH at a ratio of 1:100:70 and Ad-GMBS-ChiSH at a ratio of 1:100:700 at 1000 Ad particles/cell. Each point represents the
mean 6 S.D. (n=3). **P,0.001 (Student’s t-test).
doi:10.1371/journal.pone.0012085.g006
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the other hand, the new physical characteristics of the chitosan-
modified Ad may also contribute to the observed viral infection
results. Zeta potential measurements have shown that Ad capsids
bear a significantly negative charge. The surface charges of viral
vectors can significantly affect the level of infection [42,43].
Adenoviral infection is inhibited due to static repulsion between
the negatively charged sialic acid residues on the cell surface and
the Ad [44]. Positively charged chitosan-SH effectively masks and
neutralizes the groups responsible for the repulsive charge and
produces an environment that favors nonspecific interaction of the
virus with the cell membrane.
The infection efficiencies of the unmodified Ads and chitosan-
modified Ads at different ratios (1:1:7, 1:1:70, 1:10:7 and 1:10:70)
depended on the number of virus particles in the medium (Fig. 3).
Accordingly, the transgene expression depends on the number of
Ad particles entering cells. However, the infection efficiencies of
chitosan-modified Ad at ratios of 1:100:7 and 1:100:70 were not
significantly greater than those of control cells. This indicates that
chitosan-modified Ad at ratios of 1:100:7 and 1:100:70 could not
successfully enter cells due to insufficient amounts of chitosan to
mask the negatively charged Ad, which have already lost their
innate infection ability.
Ultimately, the goal of gene therapy is to transfer genes to tissues
and to affect pathophysiological processes. The topical application
of viral vectors takes advantage of the superficial location of the
corneal epithelium and requires minimally invasive techniques. The
integrity of the corneal epithelial layer has consistently been found
to profoundly reduce the efficiency of gene transfer. Specifically, an
intact epithelium is a poor substrate for gene therapy. Attempts to
transfer markers or biologically active genes by the direct
application of adenoviral vectors have demonstrated poor epithelial
geneexpression.Theprecisemechanismforthisapparentresistance
of intact epithelium is not yet understood; however, the presence of
superficial ocular surface barriers (i.e., tear film constituents) or the
relatively low rate of cell division of intact epithelium may play a
role [45]. Furthermore, chitosan-coated nanocarriers have a great
affinity for corneal and conjunctival epithelial cells [35]. Similarly,
nanoparticles made solely of chitosan exhibit a facilitated
interaction with the cornea and conjunctiva, where they remain
for more than 24 hours [38]. Based on these observations, we
presume that chitosan-modified Ad may benefit from some of these
advantages, and we applied chitosan-modified Ad in the right eye
every 30 minutes for 6 hours to increase the infectious efficiency in
the ocular surface. Although the efficiency of the developed reagent
is poor and requires long exposure,ourmethod is able to function in
an in vivo system to increase the infection possibilities as compared to
previously employed methods.
We also carried out experiments on rats immunized with Ad
vectors by intranasal instillation, and serum antibody titers were
monitored over time until the antibody titers were between 25,000
and 50,000 at the time of challenge with topical Ad-GMBS-
ChiSH (1:100:700). The period of time between immunization
and secondary challenge was 5 weeks. The corneal tissues were
then harvested and cryosectioned. We found that corneal sections
treated with Ad-GMBS-ChiSH (1:100:700) revealed strong
fluorescence localized throughout the corneal epithelial cells
uniformly in all six rats (Fig. 9F). Our data support the idea that
the covalently conjugated Ad is resistant to neutralizing anti-Ad
antibodies and could be used to express a transgene in the ocular
surface. Compared to PEG-modified Ad [15], chitosan-modified
Ad at a ratio of 1:10:700 (Ad:GMBS:ChiSH) protected viruses
from antibody neutralization at a low concentration. We reason
that, unlike PEG, chitosan has a rigid structure of hexose to allow
Figure 7. Fluorescence photomicrographs of primary cultured corneal epithelial cells infected with unmodified Ad (A)–(D), Ad-
GMBS-ChiSH at a ratio of 1:1:7 (E)–(H), Ad-GMBS-ChiSH at a ratio of 1:1:70 (I)–(L), Ad-GMBS-ChiSH at a ratio of 1:1:700 (M)–(P), Ad-
GMBS-ChiSH at a ratio of 1:10:7 (Q)–(T), Ad-GMBS-ChiSH at a ratio of 1:10:70 (U)–(X) and Ad-GMBS-ChiSH at a ratio of 1:10:700 (Y)–
(AB) at 1000 Ad particles/cell in the absence or presence of neutralizing antibody. Magnification=1006.
doi:10.1371/journal.pone.0012085.g007
Figure 8. Infection efficiency (A) and relative fluorescent intensity (B) from flow-cytometric analysis of corneal epithelial cells
infected with unmodified Ad or chitosan-modified Ad at different ratios at 1000 Ad particles/cell in the absence or presence of
neutralizing antibody. Each point represents the mean 6 S.D. (n=3). *P,0.05 (Student’s t-test).
doi:10.1371/journal.pone.0012085.g008
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concentration of neutralizing antibody.
In conclusion, chitosan can provide a great platform for
chemical modification of Ad. It permits the incorporation of a
range of targeting molecules and other biological effectors.
Therefore, chitosan-modified Ad provides promising potential
for further in vivo studies.
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